Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 20,671 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Peripheral Blood Clear all

Conditions: Cancer
Interventions: Prehabilitation Intervention; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diabetes Mellitus, Hyperglycemia
Interventions: Not listed
Lead sponsor: Dental Practice-Based Research Network; Network
Eligibility: 19 Years and older
Enrollment: 498 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Birmingham, Alabama • Gainesville, Florida • Minneapolis, Minnesota + 1 more

Conditions: Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Renal Cell Carcinoma, Renal Cell Carcinoma, Unresectable Advanced Renal Cell Carcinoma, Metastatic Ncc Renal Cell Carcinoma
Interventions: Cabozantinib, Nivolumab, Ipilimumab; Drug
Lead sponsor: Bradley A. McGregor, MD; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Dallas, Texas

Conditions: Colorectal Cancer, Early Onset Colorectal Cancer, Diet Habit, Risk Reduction
Interventions: Semi Quantitative Food Frequency Questionnaire (SQFFQ); Behavioral
Lead sponsor: San Raffaele University; Other
Eligibility: 18 Years to 49 Years
Enrollment: 2,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2035
U.S. locations: 2
States / cities: Denver, Colorado • Chicago, Illinois

Conditions: Human Immunodeficiency Virus Infection, Hepatitis C
Interventions: Not listed
Lead sponsor: G & W Laboratories Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 7
States / cities: Fort Lauderdale, Florida • Douglasville, Georgia • Baltimore, Maryland + 1 more

Conditions: Infections
Interventions: Cefazolin 3gm for Injection USP and Dextrose Injection USP; Drug
Lead sponsor: B. Braun Medical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Columbus, Georgia • Oklahoma City, Oklahoma

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: biologic sample preservation procedure; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 1,294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 292
States / cities: Fort Smith, Arkansas • Berkeley, California • Burbank, California + 192 more

Conditions: Bladder Cancer
Interventions: Nivolumab; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Salt Lake City, Utah

Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions: paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride; Drug · Biological
Lead sponsor: University of Washington; Other
Eligibility: Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 17
States / cities: Anchorage, Alaska • Yuma, Arizona • Lewiston, Idaho + 12 more

Conditions: Anemia, Small Bowel Bleeding, Angioectasias
Interventions: Tranexamic Acid (TXA) treatment, Placebo; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Myeloid Chimerism
Interventions: CliniMACS CD34 Reagent; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2037
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 50 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 45 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sickle Red Blood Cell, Fetal Hemoglobin, Oxidative Stress
Interventions: Broccosprouts® (Brassica Protection Products LLC) homogenate; Dietary Supplement
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Actinic Keratosis (AK)
Interventions: Investigational drug, Photodynamic therapy; Drug · Device
Lead sponsor: Sun Pharmaceutical Industries Limited; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: PolyTregs+IL-2; Biological
Lead sponsor: Jeffrey Bluestone; Other
Eligibility: 18 Years to 45 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: San Francisco, California • New Haven, Connecticut

Conditions: Myeloma
Interventions: G-CSF, Plerixafor, Apheresis, Melphalan, Stem cell re-infusion, Basiliximab, CliniMACS CD25 microbeads and cell sorter; Drug · Procedure · Device
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Melanoma Stage III, Melanoma Stage IV
Interventions: Nivolumab, BMS-986205, Ipilimumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Accelerometry, Aerobic Exercise, Biospecimen Collection, Electronic Health Record Review, Exercise Counseling, Internet-Based Intervention, Interview, Physical Performance Testing, Resistance Training, Survey Administration, Tailored Intervention; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 60 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Gastric Cancer
Interventions: 5-Fluorouracil, Capecitabine, Cisplatin, Pertuzumab, Placebo, Trastuzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 780 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 10
States / cities: Fort Myers, Florida • Chicago, Illinois • Goshen, Indiana + 7 more

Conditions: Multiple Sclerosis
Interventions: Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate; Drug · Biological
Lead sponsor: Biogen; Industry
Eligibility: Female only
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 2
States / cities: Aurora, Colorado • Durham, North Carolina

Conditions: Postoperative Pain
Interventions: Bupivacaine, Lidocaine, Thrombin, Tranexamic acid, Aminocaproic acid; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Lewy Body Dementia (LBD), Alzheimer Dementia (AD)
Interventions: C-11 ER-176, Blood Test; Drug · Diagnostic Test
Lead sponsor: Val Lowe; Other
Eligibility: 60 Years and older
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

A Nutrition & Exercise Prehabilitation Intervention on Inflammatory Biomarkers in AI Cancer Patients

DPBRN Blood Sugar Testing in Dental Patients

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults

S9910, Collecting and Storing Blood and Bone Marrow Samples From Patients With Hematologic Cancer

Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Tranexamic Acid for The Management of Bleeding Gastrointestinal Angioectasias

Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels

Pilot Study: Effects of G-CSF on T Cell Function

Blood Biomarker in Early Parkinson's Disease

The Effect of Ethanol on Brain Activity

Effect of Broccoli Sprouts Homogenate on SS RBC

An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face

T1DM Immunotherapy Using Polyclonal Tregs + IL-2

Stem Cell Transplantation for Patients With Multiple Myeloma

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma

A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation

Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias